ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
